MEDICO · Medico Remedies Ltd · Biotechnology & Drugs
MEDICO · Medico Remedies Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
67.6% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹69 Cr
Revenue YoY
PAT YoY
+38.5%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
4.1
P/S (TTM)
1.3
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| MEDICO (this stock) | 23 | 4.1 | +5.8% | +18.3% | 0.25 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-09-25 | MEDICO | 0 | 0 | STRONG | BULK |
| 2026-08-04 | MEDICO | 430000 | 1 | STRONG | BULK |
News timeline
- loweconomictimes.indiatimes.com· 29 Sept 2026, 05:46 pmMedico Remedies among 5 Healthcare stocks hitting 52-week low; slipped up to 48% in a month - New Bottoms
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedThe annual report of Medico Remedies Limited for FY2025-26 highlights the company's financial performance, including a total turnover of Rs. 20,637 Lakhs and a net profit after tax of Rs. 1,311 Lakhs. The report outlines the company's compliance with various regulations and governance standards, including the absence of material changes affecting its financial position. It also discusses the company's strategic focus on leveraging global patent expiries, reducing dependency on China for raw materials, and increasing PE investments to drive growth in the pharmaceutical sector. The report mentions the implementation of ERP solutions to enhance internal controls and operational efficiency.
- The company's financial performance shows growth in turnover and net profit compared to the previous year.
- Strategic focus on leveraging global patent expiries and reducing dependency on China for raw materials.
- Implementation of ERP solutions to enhance internal controls and operational efficiency.
- Compliance with regulatory requirements and governance standards.
Key takeaway: Medico Remedies Limited is focusing on strategic growth drivers such as leveraging global patent expiries and reducing dependency on China, while enhancing internal controls through ERP solutions to ensure operational efficiency and compliance.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesEarlier (1-3 years ago)
The company received notices for alleged non-compliances from stock exchanges, including penalties from NSE and BSE, but the penalties were waived after the company filed waiver applications.
The company received communication confirming waiver of entire fine amount levied by NSE and BSE under SOP guidelines for alleged non-compliance under various SEBI (LODR) Regulations, 2015 in the previous reporting period.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
The company had substantial defaults in payments to depositors, debenture holders, shareholders (in case of no payment of declared dividends), and creditors.
Routine disclosures
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
Medico Remedies Limited made contributions to 'Kapurlal Tribhovandas Mehta Charitable Trust,' a trust jointly controlled by the company's KMPs, which is a related party.
The company made contributions to 'Kapurlal Tribhovandas Mehta Charitable Trust,' a related party jointly controlled by the KMPs of Medico Remedies Limited, to fulfill its CSR obligations.